<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0204870.ref021">
 <label>21</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Roemer</surname>
   <given-names>MGM</given-names>
  </name>, 
  <name>
   <surname>Redd</surname>
   <given-names>RA</given-names>
  </name>, 
  <name>
   <surname>Cader</surname>
   <given-names>FZ</given-names>
  </name>, 
  <name>
   <surname>Pak</surname>
   <given-names>CJ</given-names>
  </name>, 
  <name>
   <surname>Abdelrahman</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Ouyang</surname>
   <given-names>J</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma</article-title>. 
  <source>Journal of clinical oncology: official journal of the American Society of Clinical Oncology</source>. 
  <year>2018</year>;
  <volume>36</volume>(
  <issue>10</issue>):
  <fpage>942</fpage>â€“
  <lpage>50</lpage>. 
  <pub-id pub-id-type="doi">10.1200/JCO.2017.77.3994</pub-id> ; PubMed Central PMCID: PMCPMC5877802.
  <?supplied-pmid 29394125?>
  <pub-id pub-id-type="pmid">29394125</pub-id>
 </mixed-citation>
</ref>
